Health Professional Radio conducted an interview with Dr. Jamie Coffin, Sema4 President and COO. Among other things, he covered Sema4’s large-scale and accurate COVID-19 testing, Sema4’s COVID-19 testing solutions for schools and universities, and the importance of testing.
Sema4 Gives Janssen Access to Potential Competitive Advantage in Recruiting Oncology Patients
TrialSite News featured Sema4’s research agreement with Janssen Research & Development, LLC. The piece examines how Sema4 and Janssen will collaborate to identify patients diagnosed with cancer who could be possible candidates for oncology trials.
Sema4 Announces Collaboration with Janssen on Optimizing Oncology Clinical Trials
Sema4 has entered into a research agreement with Janssen Research & Development, LLC to leverage advanced data analytics and genomic testing to improve recruitment of patients in oncology clinical trials.
Bloomberg Radio conducted a live interview with Dr. Eric Schadt, Sema4 Founder and CEO. Among other things, he covered the current status of COVID-19 testing in the U.S. and the work Sema4 is doing to combat COVID-19. Dr. Schadt’s interview starts at five minutes and 48 seconds in the link below. LISTEN HERE
TechCrunch | 07.29.20
Using population health analysis to improve patient care brings Sema4 a $1.1 billion valuation
Sema4’s $121 million financing came from BlackRock, Deerfield and Moore Strategic Ventures, and follows only 12 months after another $120 million institutional financing from investors, including Blackstone, Section 32, Oak HC/FT, Decheng and the Connecticut Innovation Fund.
Sema4 Closes $121 Million Series C Led by BlackRock
Sema4 announces that BlackRock led its oversubscribed Series C financing of $121 million at a post-money valuation of over $1 billion. Additional new investors include Deerfield and Moore Strategic Ventures.